Garrett L. Walsh
University of Texas MD Anderson Cancer Center
CancerRadiologySurgeryOncologyRetrospective cohort studyStage (cooking)Respiratory diseaseLung cancerSurvival rateChemotherapyEsophagectomyCarcinomaLungChemoradiotherapyEsophageal cancerAdenocarcinomaPerioperativeRadiation therapyMedicineGastroenterology
287Publications
62H-index
11.9kCitations
Publications 290
Newest
#1Nicolas Zhou (University of Texas MD Anderson Cancer Center)H-Index: 3
#2David C. Rice (University of Texas MD Anderson Cancer Center)H-Index: 52
Last. Boris Sepesi (University of Texas MD Anderson Cancer Center)H-Index: 22
view all 15 authors...
Abstract Background Whether extrapleural pneumonectomy (EPP) or extended pleurectomy/decortication (P/D) is the optimal resection for malignant pleural mesothelioma (MPM) remains controversial. We therefore compared perioperative outcomes and long-term survival of patients who underwent EPP vs P/D. Methods Patients with the diagnosis of MPM who underwent either EPP or P/D from 2000 to 2019 were identified from our departmental database. Propensity score matching was performed to minimize potenti...
Source
#1Nicolas Zhou (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Erin M. Corsini (University of Texas MD Anderson Cancer Center)H-Index: 13
Last. David C. Rice (University of Texas MD Anderson Cancer Center)H-Index: 52
view all 12 authors...
BACKGROUND It is unclear whetherrobotic segmentectomies are advantageous. We describe our experience with the robot, comparing patient populations and outcomes with videoscopic thoracic surgery (VATS) and open resection. METHODS Patients who received anatomic segmentectomy from 2004-2019 were reviewed. Resection methods were categorized as robotic, VATS, or open. Segmentectomies were categorized as simple or complex. Baseline characteristics and perioperative outcomes were analyzed from 2015-201...
Source
#1Erin M. Corsini (University of Texas MD Anderson Cancer Center)H-Index: 13
#2Kyle G. Mitchell (University of Texas MD Anderson Cancer Center)H-Index: 7
Last. Wayne L. Hofstetter (University of Texas MD Anderson Cancer Center)H-Index: 53
view all 15 authors...
Source
#1Erin M. Corsini (University of Texas MD Anderson Cancer Center)H-Index: 13
#2Nicolas Zhou (University of Texas MD Anderson Cancer Center)H-Index: 3
Last. Wayne L. Hofstetter (University of Texas MD Anderson Cancer Center)H-Index: 53
view all 11 authors...
Source
#1Jacqueline K. Olive (BCM: Baylor College of Medicine)H-Index: 6
#2Nicolas Zhou (University of Texas MD Anderson Cancer Center)H-Index: 3
Last. Mara B. Antonoff (University of Texas MD Anderson Cancer Center)H-Index: 17
view all 12 authors...
Abstract Background Psychiatric comorbidities (PC) have been associated with poor surgical outcomes in several malignancies. However, the impact of PC on surgical outcomes for non-small cell lung cancer (NSCLC) remains largely unknown. Methods NSCLC patients who underwent pulmonary resection at a single institution between 2006-2017 were included. Presence of preoperative PC was identified by documented diagnostic codes. Demographic, histopathologic, perioperative, and survival data were analyze...
Source
#1Nicolas Zhou (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Matthew J. Bott (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 14
Last. Stephen G. ChunH-Index: 6
view all 21 authors...
3 CitationsSource
#1Tina Cascone (University of Texas MD Anderson Cancer Center)H-Index: 26
#2William N. William (University of Texas MD Anderson Cancer Center)H-Index: 35
Last. Boris Sepesi (University of Texas MD Anderson Cancer Center)H-Index: 22
view all 53 authors...
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment in operable NSCLC remain unclear. We report the results of the phase 2 randomized NEOSTAR trial (NCT03158129) of neoadjuvant nivolumab or nivolumab + ipilimumab followed by surgery in 44 patients with operable NSCLC, using major pathologic response (MPR) as the primary endpoint. The MPR rate for each treatment arm was test...
3 CitationsSource
#1Erin M. Corsini (University of Texas MD Anderson Cancer Center)H-Index: 13
#2Kyle G. Mitchell (University of Texas MD Anderson Cancer Center)H-Index: 7
Last. Wayne L. Hofstetter (University of Texas MD Anderson Cancer Center)H-Index: 53
view all 13 authors...
BACKGROUND Most patients undergoing esophagectomy will experience intermittent reflux of gastric and biliary content into the remnant esophagus postoperatively. The incidence of new or recurrent intestinal metaplasia following chemoradiation and surgery has not been well-described. Furthermore, post-resection guidelines do not exist regarding surveillance for metaplasia in the esophageal remnant. METHODS Patients undergoing Ivor Lewis esophagectomy after concurrent chemoradiation for a diagnosis...
Source
#1Erin M. Corsini (University of Texas MD Anderson Cancer Center)H-Index: 13
#2Wayne L. Hofstetter (University of Texas MD Anderson Cancer Center)H-Index: 53
Last. Garrett L. Walsh (University of Texas MD Anderson Cancer Center)H-Index: 62
view all 13 authors...
Abstract Objectives Recent evidence has shown an association between postoperative ketorolac use and anastomotic leak in patients undergoing intestinal and colorectal operations, but this relationship has been minimally explored following esophagectomy. As the use of non-opioid pain control and enhanced recovery protocols are increasingly prioritized, determination of a possible correlation between perioperative ketorolac use and leak is essential. Methods Records of patients undergoing esophage...
3 CitationsSource
#1Erin M. Corsini (University of Texas MD Anderson Cancer Center)H-Index: 13
#2Annikka Weissferdt (University of Texas MD Anderson Cancer Center)H-Index: 20
Last. Boris Sepesi (University of Texas MD Anderson Cancer Center)H-Index: 22
view all 16 authors...
OBJECTIVES Major pathological response (MPR) is prognostic of outcomes for patients with non-small-cell lung cancer following neoadjuvant chemotherapy and is used as the primary end point in neoadjuvant immunotherapy trials. We studied the influence of pathological nodal disease on patterns and timing of recurrence among patients with MPR. METHODS Patients treated with neoadjuvant chemotherapy for stages I-III non-small-cell lung cancer were identified. Surgical specimens were histopathologicall...
1 CitationsSource